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Abstract-A family of receptor subtypes, defined either by molecular (mlm5) or pharmacological 
(MLM4) analysis. mediates muscarinic cholinecgic neurotransmission in brain. The distribution and 
functions of the m3 receptor protein in brain and its relation to M3 ligand binding sites are poorly 
undersrood. To better characterize the native brain receptors. subtype-specific antibodies reactive with 
the putative third inner loops were used: (i) to measure the abundance of m3 protein and its 
regional distribution in rat brain by immunoprecipitation; (ii) to determine the cellular and subcellular 
distribution of m3 protein by light microscopic immunocytochemistry; and (iii) to compare the 
dist~bution of m3 immunorea~tIvity with the autoradiographic dist~bution of M3 binding sites labeled 
by [3~]4-diphenylacetoxv-~-methy1 piperidine methioxide in the presence of antagonists selective for the 
other receptor binding Ltes. The m3 protein, measured by immunoprecipitation, accounted for 5-10% 
of total solubilized receptors in all brain regions studied. lmmunocytochemistry also revealed a widespread 
distribution of m3-like immunoreactivity, and localized the subtype to discrete neuronal populations 
and distinct subceliular compartments. The distribution of m3 protein was consistent with the 
messenger RNA expression, and like M3 binding sites, the protein was enriched in limbic cortical regions, 
striatum, hippocampus, anterior thalamic nuclei, superior colliculus and pontine nuclei. However, m3 
immunoreactivity and M3 binding were differentially localized in regions and lamina of cortex and 
hippocampus. 
The results confirm the presence of m3 protein in brain, its law abundance compared to other mu~rinic 
receptor subtypes, and provide the first immunocytochemical map of its precise localization. The 
distribution of m3 suggests that it mediates a wide variety of cholinergic processes in brain, including 
possible roles in learning and memory, motor function and behavioral state control. However, since the 
distribution of the molecularly-defined receptor protein is distinct from the pharmacologically-de~ned M3 
binding site, investigations of the functions of m3 in brain must await developm~t of more selective 
ligands or use of non-pharmacological approaches 
Muscarinic acetylcholine receptor subtypes mediate 
diverse cholinergic effects in brain and other tissues. 
The subtypes are classified either pharmacologically 
by differential binding affinities for antagonists 
(M1-M4)36 or genetically by direct sequence analysis 
(m1-m5).2~“,Z6 The use of two classification schemes 
and a variety of methods for identification of receptor 
binding sites, mRNA and proteins have led to con- 
siderable uncertainty regarding the distributions 
and functions of the subtypes. A general corres- 
pondence between Ml-M4 binding sites and the 
respective ml-m4 gene products (proteins) has been 
suggested,s~“~z2~3y based largely on the binding affini- 
ties of the cloned receptors. However, the subtypes 
have a high degree of sequence homology in the 
putative transmembrane domains where ligand bind- 
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Abbreviations: AF-DX 116, 1 I-([2-((diethylamino)methyl}- 
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ing occurs,” making development of more highly 
selective drugs for ml-m5 difficult.4,b For this reason. 
the relationships between native binding sites in 
brain and the molecularIy distinguish~ proteins are 
uncertain.‘6.‘9 
Methodological improvements for receptor 
localization, including autoradiography with more 
selective ligands and immun~yt~hem~st~ with sub- 
type-selective antibodies, have begun to clarify the 
distributions of the subtypes and the degree of corre- 
spondence between the classification systems. Ml 
sites defined pha~acologi~lly by ~gh-a~nity bind- 
ing of pirenzepine and related compounds,9.B and 
ml protein measured by immunoprecipitation,‘6 ‘p,37 
are both present at highest levels in neocortex, hippo- 
campus and striatum? with much lower levels in 
thalamus and other hindbrain structures. Immuno- 
cytochemical studies have recently localized ml to 
postsynaptic sites on the somata and dendrites of 
most neurons in cortex, hip~ampus and stria- 
tum.*0~‘6~i4 M2 sites defined pha~acolo~i~ally by 
low affinity with pirenzepine and high affinity with 
AF-DX 116 and other compounds,“,36,‘y and m2 
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pr&ein measured by ~mmunoprecipltation’“‘” are 
both widespread in brain. Immunccytochcmical stud- 
ies have more precisely localized m2 to cbolinergic 
and non-cholinergic neurons and both yre- and post- 
synaptic sites. i”,1S,24 Although these comparisons 
show a general agreement in the distributions of Vl1 
and ml, and M2 and m2, the other subtypes compl.i- 
cate this apparent correspondence. Fnr example. 
the m4 protein is abundant in forebrain regions and 
likely contributes TV both Ivli and M? binding 
sites.“*” Indeed, m3, 124 and n-15 all have interme- 
diate birlding aRinities for Ml- and MZ-prrferklg 
ligandsT6 and the distributmns of the mRNA and/or 
proteins overlap with the other muscarinie proteins, 
DitSiculry measuring and visualizing non-MljM2 
and non-mfjm2 subtypes by both autoradiography 
and tmmunocytochemistry has precluded further 
comparisons. 
Recentfy, independent methods for Iocalizing %I\13 
birding sites and m3 receptor immunoreactivity 
have been developed. Znhieta and I%$” described 
receptor autoradiographic techniques using [%]4- 
DAMP in the presence of unlabeled pirenzepine and 
AF-DX It6 to visualize M3 binding sites sekcti~ly 
in a wide distribution in brain. Subtype-specific anti- 
bodies reactive with m3 protein have been developed 
in our k&oratory” and others,?’ and although the 
protein has been detected by irnrnunoprffipitation, 
the precise regional and cel!ular distribution of m3 
in brain has not been described using immunocgto- 
chernicai methods. The goals of the present study 
were to further investigate the distributions r>i’ ITI? 
hy immunnprecipitation and immunncyt4xhemistr~, 
and to compare these findings with the distribution of 
M3 binding siterr. 
EXPERIMENTAL FROCFLWRES 
Antisera and affinity-purified rabbit poly&nal antibodies 
reactive with the putative third intracellular loops of the m3 
receptor were generated and characterized previousIj’1”‘7 
This region is highly divergent among aft muscarinic 
and other identified reoeptors. In specificity tests using he 
entirc Famtly of cloned receptors expressed in transfected 
mammalian cells, the antibodies are selective for the 
m3 protein by immunoprecipitationn’B and Western blot 
analysis ‘0 Moreover, in spee&city tests using native 
@H]NMS,5 &d !bey also react-w& a sin& pmtein on 
immunoblots of brain membranes that corresponds to the 
size of the cloned protein.“’ Antisera selective for the othet 
muscarinic receptor subtypes ml-m5 were also used for 
immunaprccipitation studies and were characterized in 
detail previously. 56 
Muscarinic receptor subtypes were measured by immuno- 
nrecidtatmn’* in dissected rat brain regions, including 
&n&l cortex, hippocampal FMnation, caudateputamen, 
thalamus and the ~cnfral midbtain (including the substansia 
nigrs). Ten male rat3 (Harlan Sprague-Dawley, Indiana- 
polis. IN) were killed by decnpitatian, t:ne brains were 
removed, &secled and rhen homogenized bh band 111 a @asa 
homogenizer at 4 C in IO vtdurries (w,‘v) of Tris EDTA 
huser fTE: IO t&l Tris. 1 mM EDT& pM 7.5) addition& 
containing 0.2 mM phen~imeth~lsulfonyl fluoride. t ~1 %I 
pepstati? A, i :rg!mt leupepkn iind tUgg;inl scl~hcan 
trypsin inhibitor to retard protcul~s~s. Honngenatcs WCK 
centrifuged at 7(~.00ll~ for Ii! nvn end the supernatant 
discarded. Pellets were res;lspended in half 16 oripin~:l 
volume of TE and aliquats were frozen at “-70 C hci‘orc 
6geriate %as incubated at b’C for I 3, “and t&n centrifuged 
at 12,MM g for 30 min. The total numbers of soiubilized 
muscat%& receprors in the supernatants Eere determined b!: 
gel filtration as described below. For subtype immuno- 
precip;tations, solubilized receptors were labeled wi:h 
10 nk4 @2/h’MS (dew-mined by saturation binding >tnaJysis 
to lube1 the vast majonty of soiubihzed receptors), and 
parallel sampies mere each mixed with a single antIserum 
specific ?or one of the ml -m”, rrr;cptors (tinaf dilution 1: SUI 
at 4-C far 4 k, and then goat anti-rabbit (final diiutmn ! : lo! 
was added fo B final volume of 285gI ax! mcohted 
overnight to co-precipitate immune compiexes (containing 
rapidly by rcsuspccsion~ in im cold TED butk. rect:n- 
trifuged and radioactivity in the pellets was determined 1~) 
liquid scintillation spectroscopy. Control icna~unuprecip!+ 
tates using non-immune sera nr irrelevant antisera irractive 
with dopamine receptor subtypes” and sodium-poorassium 
ATPase) were perIbrmed in eceb assay to determine ron- 
specific trapping of [‘H]NMS, and these vz!ues wcrc 
subtracted From ex;lerimentJ samples. 
Total muscaridic reccator binding in the homogenate!: 
was cetermined by mem&ane filtrati& assay a?xer I&ling 
m i nM 13HJNNMS @2Ci~mntoI) with I FM atrcpinc sulfate 
to &tine non+peciEc binding, as described previously.’ 
Total solubilized muscarinic receptors were determined 
in 125 L~J aliquats of the supcmatants. diluted in TED to ii 
final v6iumcnf ?.Sml. Ro&e sssays of maximA binding 
capacity em&& an incubation time of 6 h *It 4 C 
in IO nM [“INMS. This concentration was determmcd foi- 
lowing sa&~n~ion anaalyses that wwe conducted at ligand 
concentrations between 0. I and 12 5 nM. Ncn-specific bind- 
ing was determined in the a&itional presence of 1 pM 
atropine. Receptor-bound activrty was determined by chrom 
matography of dupiicate sainplcs using Sephadex G-15 
columns wvi& a 3ml bed volume (Pharmada Biotedi Inc., 
Plscataway, NJ). Bound and free activities were duteri 
in sucasivr llxi ~1 fractions of TED and were assayed by 
liquid scintillation spectroscopy. The prak of receptor. 
bound achvity eluted at approGmat&y 1 ml, and *as 
quantified bq integration of t,k nine fractions surrounding 
the peak. The peak of activity corresponding to free 
l&and eluted in Practloas between 1.5 and 3 ml of added 
TED. Saturation of NMS bmding to solubilized receptors 
was analxsed with the Lignnd Program for computer- 
assisted, non-lin~~ir curve-fittmg.*’ So!ubilizatioc etXder?c~ 
was d&ntxi as the ratio of specific NMS binding in solubil- 
ized supcmatants to spec&ic NMS binding in the originA 
homngenatez. Protein was determined with the bitin- 
&or&& acid method.” 
Nineteen male albino rats (Charles River) Were deeply 
arlevthetizcd with chloral hydrate, perfused inrracardialljr 
with 0.9% saline, fol!owcd by 0. i M phosphate-buffered 3% 
parafiirrnaldehyrte, $1 7.4. and then lOoi buffered sucrose. 
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One animal was fixed with 2% paraformaldehyde, 0.05 M 
lysine and 0.005 M sodium periodate. Brains were immedi- 
ately removed, placed in 30% buffered sucrose for several 
days, frozen on dry ice and sectioned at 40 wrn on a 
sliding microtome. Tissue sections were processed for 
immunocytochemistry using the avidin-biotin-peroxidase 
method (Elite, Vector Labs), and developed with diamino- 
benzidine hydrochloride as described previously.‘6 Some 
sections from two tats were pretreated with hydrogen 
peroxide and sodium hydroxide to quench endogenous 
peroxidase and enhance antigen retrieval as described.’ 
Affinity-purified antibodies to m3 were used at a final 
concentration of 0.5-l .O pg/ml; this dilution was chosen to 
optimize the signal-to-noise ratio. Immunocytochemical 
controls consisted of adsorption of the receptor antibodies 
with 100 pgjml of immobilized-GST or m3i?-GST fusion 
proteins, and omission of the primary antibody. 
Autoradiographic ligand binding studies 
Three male rats (Harlan Sprague-Dawley, Indianapolis, 
IN) were killed by decapitation, and the brains rapidly 
removed and frozen in crushed dry ice. Specimens were 
covered with embedding medium (Lipshaw, Detroit, MI) 
and stored at -70°C. Quadruplicate, corona1 brain sections 
(20 pm) were obtained with the use of a cryostat microtome 
at -18°C. Two adjacent sections at each level were 
mounted on each of two gelatin-subbed microscope slides, 
thaw-mounted and allowed to dry at room temperature. 
Slides were then stored at -70°C until use in binding 
assays. Autoradiographic binding assays were performed as 
described previously. 43 Slides were washed in buffer to 
remove endogenous interfering substances, incubated in the 
presence of 5 nM[jH]4-DAMP (82.6 Ci/mmol) for 60 min to 
label muscarinic receptors, followed by two successive 1 min 
incubations in fresh buffer at 4°C to remove non-specific 
binding. Slides were then dipped briefly in cold distilled 
water to remove excess buffer salts and allowed to air-dry 
At each anatomic level. one slide was prepared for evalu- 
ation of total 4-DAMP binding, as described above, while 
the second slide was processed to enhance the relative 
contribution of M3 receptors. This was accomplished by 
the addition of 1 ,IJM concentrations of unlabeled AF-DX 
116 and pirenzepine to the 13H]4-DAMP incubation. This 
protocol results in 95% reductions in the binding of 4. 
DAMP to Ml and M2 receptors, while labeling 40% of the 
M3 receptors; in a hypothetical region conraining equal 
admixtures of Ml, M2 and M3 receptors, 85% of 4-DAMP 
binding under these conditions is attributable to the 
M3 sites. Autoradiograms were generated by apposition 
of slides to tritium-sensitive X-ray film (Hyperfilm- 
3H, Amersham, Arlington Heights, IL) for four weeks. 
Autoradiographic images were analysed with the use of 
a computer-assisted video densitometer (MCID system, 
Imaging Research, St Catherines, Ontario). 
Marerials 
AF-DX 116 and pirenzepine were the generous gift of 
Dr Karl Thomae, Gmbh, Beberach an der Riss, Germany. 
]jH]4-DAMP and [‘H]NMS were purchased from New 
England Nuclear (Boston, MA). Atropine sulfate was 
obtained from Sigma Chemical Co. (St Louis, MO). 
RESULTS 
Immunoprecipitation assay of muscarinic receptors 
Saturation analyses of [3H]NMS binding to solubil- 
ized muscarinic receptors from whole brain were 
consistent with a homogeneous population of binding 
sites in each of three independent assays when 
analysed individually, and again in combination 
.2 I 0.0 0.2 0.4 a Bound, nM 
c 
z 0.0 1 
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Fig. I. Binding of 13H]NMS to solubilized muscarinic recep: 
tors from rat brain. Aliquots of solubilized receptors were 
incubated in the presence of varying concentrations of 
[)H]NMS, and bound activity separated by Sephadex gel 
chromatography. Total binding (solid line, closed circles) 
and non-specific binding (dashed line, open circles) as 
estimated in the presence of 1 FM atropine are depicted 
from one of three independent experiments. Inset: Scatchard 
(Rosenthal) plot of specific NMS binding. The data are 
consistent with hgand binding to a homogeneous receptor 
population. 
(Fig. 1). The estimated equilibrium dissociation con- 
stant was 0.30 + 0.03 nM (mean) SD.), with Hill 
coefficients ranging between 0.85 and 0.96. On this 
basis, 10 nM [‘HINMS was chosen to provide essen- 
tially complete saturation of solubilized receptors for 
immunoprecipitation studies. This concentration 
of radioligand resulted in somewhat higher but 
acceptable levels of background compared to pre- 
vious studies using 1 nM [3H]NMS,‘6 with non- 
specific trapping of (‘H]NMS averaging 19% of total 
specific solubilized receptors added to each assay 
(ranging from 13% in striatum to 23% in ventral 
midbrain). There were no significant differences in 
background levels with non-immune sera or different 
control antisera to dopamine receptors and other 
brain proteins. This indicates that variations in 
the immunoglobulin concentrations as occurs among 
different antisera do not influence recovery of 
muscarinic receptor subtypes. 
Other factors potentially affecting the immuno- 
precipitation assay were also analysed. Dissociation 
of [‘HINMS from receptors during the itnmuno- 
precipitation process might occur due to antibody 
binding, washing or other reasons. To test these 
possibilities, solubilized receptors were incubated 
in 13H]NMS, followed by determination of bound 
activity by gel filtration. Addition of specific antisera 
or 10 PM atropine for up to 60min following the 
labeling of receptors did not reduce the recovery 
of specifically-bound activity as determined by gel 
filtration. Thus, it is unlikely that appreciable 
amounts of NMS dissociate during the imtnuno- 
precipitation procedure. Since solubilization efficien- 
cies averaged 49%, we also investigated the possible 
fate of muscarinic receptors identified in the initial 
210 A. I. Levey (‘I (II. 
Table 1. Regional analysis of m3 protein in rat bram by immunopreclpitation 
Reeion 
Specific binding* mi: 
FI td.o.m.) Percentage m3t (~rnol~m~l 
Frontal cortex 5 3783 2 563 7?4 0.08 i 0.04 
Hippocampus 5 3559 * 2x0 7+2 0.07 
5_tl 
* 0.01 
Srriatum 5 8700 * 703 0.09 & 0.0 I 
Thalamus 5 3213&122 3 * 3 0.04 * 0.01 
Midbrain 5 14 12 i- 200 I2 +h 0.04 i 0.02 
*Total specific binding of [3H]NM5 to soiubie receptors was determined by gel 
filtrstion. Non-specific binding was determined in the presence of 1 PM 
&opine and subtracted from total binding. Values reflect the mean and 
standard deviation of five independent assays, each conducted on tissues 
pooled from two animals. 
tValues shown are the percentage oi‘ total solubilized [‘IIJNMS binding sites 
recovered in immunoprecipitates with m3 antisera minus control mmunopre- 
cipitates using irrelevant antisera. 
:Corrected for solubi~ization efficiencv (see Experimental Procedures), total 
binding and [‘H]NMS specific acti& (I 80.93 d.p.m.,Jfmol). 
tissue homogenates, but not accounted for in assays 
of solubilized sites. Repeated detergent exposure 
of the residual unso~~lbili~~d tissue pellet did not 
result in additional s&bilked binding sites. Neither 
did membrane filtration binding assays detect the 
presence of residual receptors in the post-detergent 
pellet, suggesting that receptors not represented in 
the detergent supcrnatants are denatured during the 
solubil~zation procedure. 
Itnmunoprf cipifation of m 3 m ral brain 
Immunoprecipitation studies were used to deter- 
mine the abundance of m3 receptor in various 
regions of rat brain, as shown in Table I. Precipi- 
tation of this subtype accounted for S-12% of 
the total number of solubilized i3H]NMS binding 
sites. Although these levels were relatively low, the 
immunoprecipitates with m3 antisera yielded signifi- 
cantly greater [‘H]NMS recovery than control pre- 
cipitates using non-immune sera for every region 
(P < 0.05, Student’s t-test). The smallest relative 
difference between m3 and control immunoprecipi- 
tates was in frontal cortex (m3 was 21% higher than 
controls) and the largest difference in ventral mid- 
brain (m3 was 53% higher than controls). AS 
mentioned above, the use of different control antisera 
did not influence the results. The dis~~bution among 
dissected regions was also fairly uniform, with esti- 
mates of the tissue densities (corrected for solubil- 
ization efficiencies) ranging from 0.04 pmol/mg 
membrane protein in midbrain and thalamus to 
0.09 pmol/mg in striatum. 
The composition and relative abundance of the 
entire family of muscarinic receptors in rat brain are 
shown in Table 2. Recovery of muscarinic receptor 
subtypes was close to 100%, based on the sum 
of the immunoprecipitates. In frontal cortex and 
hippocampus, ml, m2 and m4 were the most abun- 
dant subtypes and each accounted for roughly one- 
quarter to one-third of the total population of 
soiubilized [3H]N~S binding sites. In str~atum, the 
m4 subtype alone accounted for nearly one-half of 
the total receptors, whereas in thalamus and mid- 
brain m2 was the most abundant subtype. The m5 
receptor was recovered at low levels in every brain 
region, and was statistically significant compared to 
controk (P < 0.05) in every case except in ventral 
midbrain. 
Light microscopic u’istribution of m3 immunoreacti~it.v 
in rut brain 
The immunocytochemica1 distribution of m3 was 
widespread in rat brain, as shown in the right cofumn 
of Fig. 2. In general, the microscopic appearance of 
the diaminobenzidine peroxidase reaction product 
was brown and finely granular, and associated with 
cell bodies, neuritic processes and neuropil. The 
density of the reaction product was routinely much 
less than as described previously for ml. m2 and 
m4.16 Sections pretreated with hydrogen peroxide and 
sodium hydroxide exhibited moderately improved 
sensitivity compared to untreated sections. Immuno- 
logical specificity was demonstrated by inhibition of 
staining after pr~~dsorption of the antisera with 
Table 2. Distribution of ml-mS in rat brain by immunoprecipitation* 
Region ml m2 m3 m4 m5 Sum 
Frontal cortex 25+4 36&1I 7i4 29F4 614 104i 14 
Hippo~ampus 3x+9 21+5 7i2 21 53 612 94f 12 
Striatum 27 + I 12i I 5*l 48 & 2 5&l 97*3 
Thalamus a-1-4 48 f 5 823 30+7 6-r-2 99* II 
Midbrain to+9 54 + 7 12 + 6 13+3 6&S 9657 
*Shown are the percentage of total soluble receptors for each subtype + S.D. Total 
soluble receptors and number of animals for each region as shown in Table 1. 
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M3 m3 
Fig. 2. Comparison of the distribution of M3 binding and m3 immunoreactivity in rat brain. Coronal 
sections were processed for visualization of M3 binding sites (left) with [-‘H]CDAMP plus unlabeled 
pirenzepine and AFDX 1S6, and aligned with sections from separate animals processed for m3 
immun~react~vit~ (right). The two markers show similar localization in most brain regions. Am, amygdala; 
Aqj aqueduct; AV, anteroventral thalamic nucleus; CA1 and CA3, helds of hippocampus; cc, corpus 
callosnm; Cg, cingulate cortex; CPU, caudate-putamen; cp, cerebral peduncle; DEn, deep endopiriform 
cortex; Ent, entorhinal cortex; Ft, frontal cortex; GP, globus pallidus; Hil, hilus: Hy, h~pothaiamus; IC, 
inferior cofliculus; MC, medial geniculate; Oc, occipital cortex: Par, parietal cortex; Pir, piriform cortex; 
F’n, pontine nuclei; PRh, perirhinal cortex; Rs, retrosplenial cortex; S, subiculum: SC. superior colliculus; 
SN, substantia nigra; Te, temporal cortex; VP. ventroposterior thalamic nucleus. Scale bar = 1 mm. 
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the i3 loop fusion protein, Control sections with 
omission of m3 antibody were routinely performed 
and showed light diamino~nzi~ne reaction product 
in occasionaf gfia, select neurons and a few other 
structures that in most cases were easily distinguished 
from antibody-treated sections; exceptions will be 
further described. Glial immunoreactivity with m3 
antibody was frequently detected, but because this 
staining was usually light and occasionalfy present in 
control sections, it is diEcult to be certain if this 
represented specific reaction product. The same is 
true of blood vessels, which were frequently associ- 
ated with immunoreactive fibers. Other descriptions 
of m3 immunoreactivity refer to specific staining not 
observed in controfs, with the intent that the term 
denotes m3 “like” jmmunoreactivity. As with any 
immunocytochemical procedure, it is not possible to 
be certain that the reaction product is localized only 
to the m3 receptor in tissue sections, despite rigorous 
characterization of antibody specificity by immuno- 
precipitatjon and immunoblotting. 
Cortical and reiated structures. In the olfactory 
bulb, m3 immunoreactivity was enriched diffusely 
in the glomeruli and moderately in the external 
plexiform layer. In the cerebral cortex, m3 immuno- 
reactivity was differentially distributed across regions 
and lamina (Figs 2, 3). Limbic regions exhibited 
highest levels in cortex, including cingulate (Fig. 3D). 
retrosplenial, piriform (Fig. 3E), entorhinal (Fig. 4) 
and insula and deep endopiriform cortex in the 
perirhinal region (Fig. 2). lmmunoreactivity was 
most dense in the neuropil in the superficial aspect of 
the mofecular layer, and in neurons and the neuro- 
pi1 in layers II/III and V (Fig. 3). Some astrogliaf 
processes also appeared lightly stained (see above). 
Neuropif immunoreactivity was mostly diffuse, but 
also associated with fine neurites and puncta. In 
the hipp~mpaf formation, entorhinal cortex (par- 
ticularIy layer II cell islands and layer V neurons/ 
neuropil) and subiculum were prominently stained. 
In hippocampus proper, cell bodies and proximal 
dendrites of many pyramidal neurons and occasion- 
ally interneurons were lightly immunoreactive, with 
more intense diffuse and pun&ate immunoreactiv~ty 
in the neuropif in the stratum lacunosum moleculare, 
deep aspects of the stratum radiatum and stratum 
oriens, with CA3 greater than CA1 (Fig. 4). In the 
dentate gyrus, neuropil immunoreactivity was most 
dense in the superficial molecular layer and the hilus, 
with little immunoreactjvity in the granule celfs. 
Amygdafa nuclei with the most dense m3 immuno- 
reactivity were the basofateral and central nuclei 
(Fig. 3F). 
Subcortical forebrain structures. The slriatum dis- 
played among the highest densities of m3 immuno- 
reactivity in brain (Figs 2, 3F). Diffuse and finely 
punctate neuropif immunoreactivity were present 
throughout dorsal striatum, nucleus accumbcns and 
olfactory tubercle, and in some cases appeared 
patchy. Striataf neurons were rarely stained, and then 
only very lightly. In the basal forebrain (Fig. 4D). 
immunoreactive neurons, proximal processes and 
puncta were present in the medial septum. nuclei of 
the diagonal band of Broca, ventral palfidum. prc- 
optic nuclei and nucleus basalis. While many of 
the large basal forebrain neurons were also lightly 
stained in control sections (Fig. 4E), m3-treated 
sections consistently yielded more intense staining of 
these neurons. The dorsofateral septum had diffuse 
neuropil m3 ~mmunor~~ctivity. The gfohus paflidus. 
entopeduncular nucleus and substantia nigra con- 
tained abundant neurites and puncta, and also 
scattered neurons that were lightly stained. Sub- 
thalamus neurons were enriched in m3 immunoreac- 
tivity compared to most other basal ganglia nuclei 
(Fig. 5E). 
Diencephalon. The anteroventral, anteromedial and 
anterodorsal nuclei displayed the most intense m3 
staining among thalamic nuclei and possibly other 
brain regions (Fig. 54). Neurons were prominent 
in the ~nterodorsal nucleus and the medial aspect 
of the anteroventral nucleus, while dense punctatc 
immunoreactivity was observed in the lateral aspect 
of the anteroventraf nucleus. Moderate levels of 
cellular immunoreactivity were present in lateral and 
medial geniculate, ventrobasai. mediodorsal. latero- 
dorsal, lateroposterior, gelatinosus, reuniens, para- 
ventricular and intralaminar nuclei. In some cases, 
remarkably large immunoreactive puncta were abun- 
dant in the lateral geniculate (Fig. 5D), ventrobasal 
and other nuclei; these profiles were often associated 
with the margins of cell bodies and rarely appeared 
as varicose swellings along axons. In the ep~thalamus 
and pretectum. immunoreactivity was present in 
neurons in lateral habenula, but not medial habenula, 
and also relatively intense in cells in the olivary 
pretectal nucleus and diffusely in the anterior pretec- 
tat nucleus (Fig. 5B). In the hypothalamus, most 
regions were more lightly stained than thafamus. with 
the exception that high fcvels of m3 immunoreactivily 
were present in neurons in the lateral mammillary 
nucleus (Fig. 5F) and in neuropil in the premammif- 
lary nucleus, and moderate levels were present in 
neurons in the paraventricular nucleus, lateral hypo- 
thalamus and diffusely in the ~entromed~al nucfeus. 
Neurons in the zona incerta were also immuno- 
reactive. 
Brainstem. Because the hindbrain regions exhibited 
generally higher levels of background staining than in 
forebrain, uncertainty exists regarding many nuclei. 
The background staining was not due to m3 anti- 
body, since it occurred in the controls even when 
the primary antibody was omitted. The following 
structures were none the fess consistently enriched in 
m3 immunoreactivity compared to controls, and the 
possibility that other nuclei express few levels of 
m3 ilnmunoreactivity cannot be dismissed. Immuno- 
reactivity in the midbrain was localized to a dense 
plexus of fibers and puncta in the neuropil in the 
superficial layer of superior colliculus, and to more 
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Fig. 3. lmmunocytochemical localization of m3 in cortex and amygdala. (A) m3 immunoreactivity in 
frontal cortex; note the relatively enriched staining of the neuropil in the outer molecular layer (I) and 
layers II-III, and in pyramidal neurons in layer V. (B) Control with omission of m3 antibody. (C) Higher 
magnification of m3 immunoreactivity in layer V cortical neurons, proximal dendrites, and frequent 
neuritic processes and puncta. (D) Cingulate cortex is enriched in m3 immunoreactivity compared to 
adjacent motor cortical areas, but the laminar distribution is similar. Note low level of background in 
corpus callosum (cc). (E) Piriform (Pir) and deep endopiriform (DE@ cortex exhibit enriched m3 
irnmunoreactivity. As in other cortical areas, note the increased staining of superficial molecular layer 
(arrow). (F) Amygdala nuclei show m3 immunoreactivity, including basolateral nucleus (BLA) and central 
nucleus (Ce). The caudateputamen (CPU) is also enriched in m3 immunoreactivity (also shown in upper 
left of panel E). Scale bars = 100 pm (A, B); 25 pm (C); 200 pm (lXF). 
weakly stained neuropil in deeper layers extending to immunoreactive, and scattered neurons throughout 
the central gray (Fig. 6C). In the pontine nuclei the reticular formation were more darkly stained than 
(Fig. 6A, B), neurons and neuropil were both densely in controls. In cerebellum, medulla and spinal cord, 
Fig. 4. Immunocyt~h~mical localization ofm3 in the hipp~ampal formation and medial septum. (A) Coronal scctton 01 
hippocampus shows m3 immunoreactivity enriched m the CA3 ncuropil compared to CA1 . and also in the dentalc yyrw 
(DG). (B) Higher magnification of m3 in CA1 and dcntatc gyrus is shown in thts photomontage Note the laminat pattcrr~s 
with immunoreactivity localized in cell bodies of pyramidal neurons (p). and relatively denw reaction product in the neuropil 
in the deeper aspects of the stratum radiatum (r), stratum lacunosum moleculare (l-m) and stratum trriens IO). The dentate 
gyrus. shown below the hippo~mpai fissure (dashed line). also expresses dense m? imm~~noreacti~,~t~. Granule cells (gc) 
express low lcvcls of m3, but the receptor is present in the neuropil in the molecular layer- (mo) UKI hilus (hi) and 0cc~tsiona1 
non-pyramtdal neurons (arrow), (C) The entorhinal cortex expresres relatively high levels of m3 immunoreactivity compared 
to other corticat regions. The receptor is enriched in the supcrlkial rrmlecular layer, stellatc neurons in layer 11, and both 
neurons and neuropil in deep layers. (D-F) Coronal sections through the medial septum (MS) and diagonal band of Broca 
(DB), prccessed for m3 immunoreactivity (D), conti-ol (E) or choline acetyitransferase immunoreactivity (F) ” Note the 
similar distributions of m3 immunoreactiviiy and cholinergic neurons, although the ncuropil is more immunoruactivc with 
the m3 antibody. The control section was processed without primary antibody, and shows low levels of background staining 
in man:~ neurons. S&c bar-s = 200 jtrn (A E). 
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Fig. 5. Immunocytochemical localization of m3 in diencephalon. (A) Rostra1 thalamus shows highly 
enriched immunoreactivity, particularly in the anterior nuclear group (anterodorsal, AD, and antero- 
ventral, AV), the midline nuclei (paraventricular, PV, and reuniens, Re) and reticular nucleus (Rt). 
(B) Caudal thalamic nuclei express moderate levels of m3 immunoreactivity, including dorsal lateral 
geniculate (LG) and lateral posterior (LP) nuclei. In pretectum. anterior pretectal (APT) and olivary 
pretectal (OPT) nuclei also express m3. (C, D) Higher magnification photomicrographs of lateral 
geniculate show m3-immunoreactive neurons and neuropil. The neurons are occasionally associated with 
dense punctate immunoreactrvity at the margins of the cell body (arrows). (E) Subthalamic nucleus (STN) 
is enriched in m3 immunoreactivity compared to other basal ganglia structures other than striatum. (F) 
In hypothalamus, the lateral mammillary (LM) neurons and neuropil show high levels of m3 immunore- 
activity, with low levels in the medial mammillary nucleus (MM). Note that white matter tracts in all 
sections show little or no immunoreactivity, including stria medullaris (sm), internal capsule (ic), medial 
lemniscus (ml), posterior commissure (pc) and cerebral peduncle (cp). Scale bars = 500 pm (A, B); 250 nm 
(C); 50 nm (D): 100 pm (E, F). 
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Fig. 6. Immunocytochemical localization of m3 m the pons and midbrain. (A) Pontine nuclei express 
relatively high levels of m3. (B) Higher magnification of pontine nuclei shows expression in cell bodies 
and diffusely in the neuropil. The low levels of staining in the cerebral peduncie were similar to controls. 
(C) The superficial layer of the superior colliculus (SC) expresses dense m3 immunoreactivity in the 
neuropil, with moderate levels in a patch (arrowheads) in deeper layers extending into the periaqueductal 
gray (PAG). Aq, aqueduct; cp, cerebral peduncle; lfp, longitudinal fasciculus pons; ml, medial lemniscus; 
PN, pontine nuclei; tfp, transverse fibers pons. Scale bars = 200 pm (A, C); 50 pm (B). 
background staining was too high to evaluate, with 
the exception of the spinal trigeminal nucleus, which 
was enriched in fine fibers, and neurons in the cranial 
and spinal somatic motor nuclei also appeared 
weakly immunoreactive. 
Comparison of m 3 immunoreactivity and M3 binding 
The regional distributions of m3 immunoreactivity 
and M3 binding to [3H]4-DAMP (in the presence 
of pirenzepine and AF-DX 116) were compared 
in matched sections from different animals (Fig. 2). 
Results of M3 binding were described in detail pre- 
viously and are uncorrected for tritium quenching.43 
The general distributions of both markers were simi- 
lar, with relatively dense levels of staining or binding 
in neocortex, hippocampus, striatum, anterior thal- 
amic nuclei, superior colliculus and pontine nuclei. 
Also. the markers were both present at moderate 
levels in lateral geniculate, medial geniculate, hypo- 
thalamus and periaqueductal gray, and they were 
both found at much lower levels in white matter 
pathways, such as corpus callosum, internal capsule, 
cerebral peduncle and medial lemniscus. There were 
also some significant differences in the distributions 
of m3 immunoreactivity versus M3 binding. For 
example, frontoparietal cortex was relatively enriched 
in M3 binding compared to the adjacent cingulate 
cortex, while the opposite pattern was found with m3 
immunoreactivity. Also, laminar differences were 
marked in hippocampus, where M3 was most 
dense in stratum oriens and stratum radiatum of 
CA1 with little binding in CA3, while m3 immunore- 
activity was most dense in the stratum lacunosum 
moleculare and deep radiatum of CA3. However, 
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minute comparisons were not attempted because of 
inherent limitations such as use of different animals 
for each marker (because of the need to use unfixed 
tissue for autoradiography and fixed tissue for 
immunocytochemistry), and likely differences in 
sensitivity and spatial resolution attainable with 
each method. 
DISCUSSION 
There are several principal findings of the present 
study. First, the low levels of m3 muscarinic acetyl- 
choline receptor protein in widespread regions of rat 
brain have confirmed earlier immunoprecipitation 
studies. Second, the light microscopic immunocyto- 
chemical findings also demonstrate a wide distri- 
bution of m3 immunoreactivity, and indicate that the 
protein is localized in specific cells and subcellular 
sites, complementing and extending previous studies 
of m3 mRNA. Third, the general distributions of 
m3 receptor protein visualized by imunocytochem- 
istry and M3 binding sites by autoradiography are 
similar but not identical, indicating that the two 
markers may not be equivalent. The findings clarify 
the localization of m3 receptor, its correspondence 
to the pharmacologically defined binding site, and 
suggest a variety of functional implications for m3 
in muscarinic cholinergic neurotransmission in the 
central nervous system. 
Abundance ofm3 and other muscarinic receptor pro- 
teins in rat brain 
Immunoprecipitation studies have been used to 
determine the proportion of m3 and other muscarinic 
receptor subtypes in dissected regions of rat brain. 
In our previous studies using 1 nM [‘H]NMS to 
label solubilized receptors, we were unable to recover 
significant levels of m3.16 In the present study, 
saturation binding analysis using the native brain 
receptor population demonstrated an equilibrium 
dissociation constant of 0.30, suggesting that solubil- 
ized receptors were incompletely (about 75%) labeled 
by 1 nM [‘H]NMS. Indeed, using higher concen- 
trations of ligand (10nM) we now recover m3 in 
widespread regions of brain. Our results indicate that 
m3 is present at low levels, accounting for only about 
i-10% of the total population of muscarinic recep- 
tors solubilized in the regions studied. However, we 
are cautious about interpreting these values, because 
despite their statistical significance, they are only 
about 20-SO% greater than control immunoprecipi- 
tates due to the higher levels of background with 
10 nM [‘HJNMS. The values more accurately reflect 
the upper limits of m3 contribution, given the saturat- 
ing ligand concentration employed and the quantitat- 
ive recovery of the receptors. None the less, our 
findings are in excellent agreement with immunopre- 
cipitation studies of Wall et al.‘* using a peptide 
antibody directed to the C-terminus of m3. Potcn- 
tially, methodological problems could result in appar- 
ently lower levels of m3 than are actually present 
in tissues, For instance, reduced solubilization of m3 
compared to other subtypes (e.g. due to possible 
differential subcellular compartmentation) or loss 
of antigenic sites (e.g. due to proteolytic cleavage 
or post-translational modifications) are theoretically 
possible. However, radioligand binding studies using 
tissue homogenates and sophisticated kinetic analy- 
ses,r6 and autoradiographic binding studiesq3 both 
generally agree with immunoprecipitation studies, 
and neither approach depends on solubilization of 
receptors. Also, since our polyclonal antibodies are 
directed to a variety of epitopes on the large i3 
loop, and the polyclonal antibodies of Wall et 01.~~ 
recognize the C-terminus, loss of both of these anti- 
genie regions is unlikely. 
Improved recovery of m3 in our immunoprecipita- 
tion assay using 10 nM [3H]NMS prompted a reanal- 
ysis of the entire family of ml-m5 receptors using a 
panel of subtype-specific antibodies (Table 2). Contri- 
butions of ml and m2 receptors to the total receptor 
populations were comparable to the results of our 
previous immunoprecipitation studies,16 as well as 
those of Wolfe and col1eagues.‘8.37 However, the levels 
of m4 in each region are about 15% higher than we 
found previously, suggesting that this subtype was 
incompletely labeled with lower concentrations of 
radiolabel. The m4 receptor now appears to be the 
predominant subtype in striatum and accounts for 
almost a third of the total muscarinic receptors in 
cortex and thalamus. These results are in excellent 
agreement with other recent immunoprecipitation 
studies.42 The m5 receptor also appeared to be 
recovered more efficiently in the present study, 
although present at very low levels throughout the 
brain. As discussed above for m3, we are unsure 
about the lower limits of measurable m5 receptors 
and the meaningfulness of these results. Our upper 
limit estimates of 5-6% of total receptors in each 
region are somewhat higher than the levels of m5 
reported by Yasuda et aL4’ (~2%) using different 
antibodies and techniques. The widespread distri- 
bution of mS protein is somewhat surprising, given 
the limited distribution of mS mRNA found by 
in sifu hybridization studies.34,41 However, differences 
in the sensitivity of the methods may explain this 
mismatch, since m5 mRNA is detectable throughout 
the brain using more sensitive polymerase chain 
reaction methods.40 Other possible explanations are 
differences in turnover, stability or subcellular distri- 
bution of the mRNA versus protein. Direct localiz- 
ation of m5 receptor protein will be necessary to 
address these issues, although our attempts using 
immunocytochemistry have not been successful and 
specific ligands for autoradiographic binding are not 
available. 
ImmunocJ;tochemical localization of m 3 
Antibodies specific to m3 have provided the first 
opportunity to determine the precise distribution 
of this subtype using immun~ytochemistry. The 
expression of m3 is widespread, consistent with 
the immunoprecipitation studies. The cellular localiz- 
ation of m3 protein also agrees well with in situ 
hybridization studies of m3 mRNA, including a close 
match in olfactory bulb. regions and layers of the 
cortex, hippocampal formation, thalamic nuclei, 
subthalamus. posterior hypothalamus. superior col- 
liculus, central gray and pontine nuclei.’ Although 
m3 mRNA is expressed in widespread regions of 
the brainstem, we are unsure of the distribution 
of protein because of problems with higher levels of 
background immu~oreactivity in the hindbrain. The 
agreement between immunocytochemical and in situ 
hybridization approaches substantiates the distri- 
bution of m3, and implicates this subtype in a wide 
variety of central nervous system processes. 
The light microscopic appearance of m3 suggests 
that this receptor may be compartmentalized in 
subcellular sites. For example. immunoreactivity in 
somata and proximal dendrites of neurons is consist- 
ent with postsynaptic distributions. The diffuse or 
punctatc appearance of the immunoreactivity, as 
occurs in the molecular layer of cortex. hippocampus, 
striatum and many thalamic nuclei, is consistent with 
either presynaptic localization in terminals or post- 
synaptic localization in dendritic spines. In structures 
with little or no intrinsic expression of m3 mRNA, 
such as striatum,’ presynaptic localization in the 
terminals of extrinsic afferent fibers may be more 
likely. In fact, we have recently confirmed the prc- 
synaptic localization of m3 in striatum by direct 
observation using immunoelecton microscopy.‘0 Pre- 
synaptic muscarinic receptors, with M3-like binding 
preferences, regulate neurotransmitter release in stria- 
turn, as well as in hippocampus and amygdala.‘“.zY.” 
Localization of m3 immunoreacti~lity at the ultra- 
structural level will be important to identify the pre- 
and postsynaptic distribution of this subtype in other 
regions. 
Although presynaptic muscarinic receptor sub- 
types are well known to regulate the release of 
acetylcholine. iZ.Z”.23~27~28~33 the molecular identity of the 
autoreceptorfs) in many brain regions is unknown. 
Several pharmacological and lesion studies have im- 
plicated M2 as an inhibitory presynaptic site modu- 
lating acetylcholine release in cortex, hippocampus 
and striatum.‘Z~2’~‘“.Zx The m2 protein may correspond 
to some of these binding sites, since the mRNA’ and 
proteinI are expressed at high levels in basal fore- 
brain and in cholinergic neurons in striatum,‘,“’ 
Moreover, immunoelectron microscopic studies have 
directly localized m2 protein to prcsynaptic sites 
which are likely to be cholinergic in necortex2” and 
striatum.‘O Other subtypes may also be autoreceptors. 
since pharmacological studies have found that 
Ml sites in basal forebrain’” and M3 sites in hippo- 
campus *O inhibit acetylcholine release. MI sites in 
cortex stimulate release as well.‘7 The m3 protein is 
a candidate for a muscarinic autoreceptor in cortex 
and hippocampus on both pharmacological and ana- 
tomical grounds. That is, its intermediate binding 
affinities for selective compounds are compatible 
with the varied pharmacologies reported for auto- 
receptors. The m3 mRNA” and, as shown here, the 
tn3 protein are expressed in basal forebrain neurons 
which may project to cortex and hippocampus. How- 
ever. the basal forebrain consists of heterogeneous 
~vtil populations, and whether m3 is expressed in the 
cholinergic neurons and also transported to terminal 
sites is unknown. Future studies to co-localize each 
receptor protein in cholinergic nerve terminals will 
be useful to clarify the molecular identity of the 
autoreceptors. 
Despite the widespread distribution of m3, localiz- 
ation of this receptor suggests that it may play a 
special role in limbic processes. For example, among 
cortical areas, the limbic regions display the most 
intense m3 immunoreactivity. including cingulate, 
retrosplenial, entorhinal, insular and piriform coriex. 
Also, the hippocampus and amygdala are enriched 
in m3. Moreover, the limbic nuclei in the anterior 
thalamu?. and the connectionally related neurons in 
the mnmmillary nuclei and posterior hypothalamus 
exhibit dense m3 immunoreactivity, Interestingly. 
many of these structures have been implicated in 
memory processes, and the diencephalic nuclei are 
also important in behavioral state control. A role 
for m3 in these cholinergic functions may have 
important clinical implications for targeting subtype- 
specific drugs in patients with memory and sleep 
disorders. 
Are nz3 and M 3 the ,mnze receptor? 
The immunocytochemical distribution of m3 was 
widespread in rat brain and generally consistent with 
the autoradiograph~c localization of M3. The most 
striking similarities were noted in deep endopiriform 
and insular cortex, striatum, anterior thalamic nuclei, 
superior colliculus, periaqueductal gray and pontine 
nuclei. These results corroborate predictions made 
previously by Zubieta and Frey.4’ who selected these 
structures as the regions in which the labeled sites 
are most likely to correspond to m3 protein. As 
discussed by these authors previously, sites labeled 
by [‘HICDAMP in the presence of pirenzepine and 
AF-DX 116 are predicted to include residual m I, m2 
and m4 receptors in regions where these proteins are 
subs~ntially higher than m3. However, those sites 
with the most enriched [jH]4-DAMP binding, as 
determined by the ratio of residual binding in the 
presence or absence of the antagonists to block 
non-M3 rcccptors, are most likely to reflect m3. The 
correspondence of the markers in the aforementioned 
regions provides evidence that ligand binding sites 
labeled by these conditions are comprised mainly of 
m3 protein. 
There are also notable differences in the distri- 
butions of m3 immunoreactivity and M3 binding sites 
in key regions and lamina of cortex and hippo- 
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campus. There are several possible explanations 
for these discrepancies. First, each probe may gain 
access to different populations of m3 receptors. 
Ligand binding is believed to reside within the trans- 
membrane domains,” while the antibodies react with 
the putative third cytoplasmic 10op.‘~ Thus, ligands 
may bind to receptors in which the antibody binding 
sites are unavailable, e.g. due to post-translational 
modifications or interactions with other membrane 
proteins. Similarly, antibodies may detect receptors in 
synthetic or degradative pathways, or other discrete 
subcellular compartments in which the proteins 
are not functional or capable of binding ligands. 
A second factor possibly contributing to areas of 
mismatch is that M3 binding patterns have not 
been corrected for tritium quenching. This is a non- 
uniform process and results in an apparent reduction 
of isotope content in white matter. Thirdly, potential 
problems with the specificity of either probe may also 
add to differences between m3 and M3. As discussed 
above, this is a recognized problem for M3 binding, 
since even in the presence of pirenzepine and AF-DX 
I16 residual binding to other subtypes is expected.“’ 
Residual binding of [‘H]4-DAMP to ml could in part 
explain the mismatch between m3 and M3 in both 
cortex and hippocampus, since ml is abundant in 
these structures and the regional and laminar patterns 
of M3 binding appears nearly identical to that 
of m1.16 Because m3 is present at low levels and 
barely detectable with our antibodies, we also cannot 
entirely exclude the possibility that m3 antibodies 
may cross-react with other brain proteins, despite 
their characterization by immunoprecipitation” 
and Western blotting analysis.“’ Regardless of the 
explanation, the m3/M3 mismatch in cortex and 
hippocampus suggests thal m3 protein and M3 bind- 
ing sites labeled with these conditions are not entirely 
equivalent. 
A correspondence between the m3 gene/protein 
and the M3 binding site defined pharmacologically 
has been suggested in several important reviews,8,“,‘* 
and such a relationship is implicit in nomenclature 
recommended by the IUPHAR muscarinic commit- 
tee.39 Using the most selective probes available for 
both the m3 protein and the M3 binding site, we have 
shown that the markers may overlap, but imprecisely. 
Other pharmacologically defined sites are also likely 
to be composites of multiple receptor proteins given 
the well recognized problems with limited selectivity 
of available ligands4.6,35 and the presence of multiple 
receptor proteins in most brain regions’6,4’ and per- 
ipheral tissues.s For these reasons, we recommend 
that investigators use strict definitions for molecular 
(ml-m5) and pharmacological (M I-M4) classifi- 
cations. Although reconciliation of dual classification 
systems would be ideal, until direct evidence proves 
otherwise, identities between these schemes should 
not be presumed. 
CONCLUSIONS 
The present study demonstrates that m3 receptor 
protein is present at low but measurable levels 
throughout discrete neuronal populations in the 
forebrain and upper brainstem. There is a close but 
imprecise relationship between m3 receptor detected 
by antibodies and M3 receptor detected by ligand 
autoradiography, suggesting that molecular and 
pharmacological classification schemes are not equiv- 
alent. However, because of the limitations inherent 
to each technique and the low abundance of this 
subtype, the receptors can be localized with the 
greatest certainty to structures that show agreement 
between m3 immunoreactivity and M3 binding. 
These structures include several Iimbic regions of 
cortex and thalamus. striatum. superior colliculus 
and pontine nuclei. This distribution suggests that 
m3jM3 mediates a variety of cholinergic func- 
tions, including possible roles in learning, memory, 
and motor and behavioral state control, and that 
this subtype is potentially a valuable target for 
therapeutic drugs for a variety of neurological and 
psychiatric disorders. 
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